Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "The Cutting Edge and Precision Medicine in Prostate Cancer"
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".
Deadline for manuscript submissions: 10 April 2023 | Viewed by 989
Special Issue Editor
Interests: machine learning; oncology; S-nitrosylation; cancer biology; immunology; prostate cancer; drug discovery; reproductive urology; molecular endocrinology; endocrine cancer; androgen deprivation therapy
Special Issue Information
Immune checkpoint inhibition (ICI) with agents such as anti-PD1, anti-PD-L1, and anti-CTLA4 has revolutionized the treatment of many tumor types. Such therapies restore antibody diversity to eliminate tumor cells that previously evaded immune detection. However, ICI is effective only in a subset of patients with prostate cancer. This limited efficacy is believed to result, in part, from tumor heterogeneity and the unique ability of prostate cancer to evolve from androgen-dependent to androgen-independent stages. This evolution involves as-yet-unclear mechanisms in the tumor microenvironment (TME) that promote immune escape under the reduced infiltration of cytotoxic T lymphocytes (CD8+ T cells).
The current Special Issue will focus on culminating and expanding on the knowledge in this area. The topics papers may focus on include (but are not limited to): drug resistance development against prostate cancer, especially against immune checkpoint inhibition; current advancements in the domain of monotherapy as well as combination therapy in suppressing prostate cancer; mechanisms in the tumor microenvironment which modulate resistance development; and past and ongoing trials which focus on overcoming resistance.
Dr. Himanshu Arora
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibition
- prostate cancer
- tumor microenvironment
- clinical trials in prostate cancer
- mechanisms in drug resistance
- immune regulation in prostate cancer